Pfizer Corporation

Amgen Fremont Inc.

Other

Osi Pharmaceuticals, Inc.

Abgenix, Inc.

James Dale Moyer

Penelope Elizabeth Miller

Jose Corvalan

Michael Gallo

Bruce D Cohen

Jean Beebe, Jr

Richard D Connell

Timothy Norris

Jeffrey W Raggon

Shama Kajiji

Sandra Leta Silberman

Michael J Morin

Barbara A Foster

Karen J Ferrante

Jean Beebe

Jose R Corvalan

An automated animal feeder is disclosed having a storage area with a top at one end and the second feeding into a dispensing module containing a dispensing tube. An auger, connected to a support and motor, extends into the second opening of the storage area. Preferably the auger support is movable along the dispensing module to vary a distance between the length of the auger at the proximal opening of the dispensing tube. A programmable control panel controls the motor and can have a display screen, speaker and programming members, or the control panel can be controlled by remote control. Power can be from at least one from the group of replaceable battery, rechargeable battery, solar or electricity, power the control panel and motor. A deflection tab extends into the dispensing tube, spaced from the auger, to prevent the accumulation food on the auger. The hanging member on the top can affixed to a stand with a post having a first end, a second end and a pivot point, the pivot point being affixed to the stand. The first end has a connection member for the hanging member and said second end has a rotation prevention member and an anchor. The post can rotate upon the release of the anchor to a predetermined distance from the ground as determined by the rotation prevention member or be locked in an upright position by said anchor.

Automated animal feeder

The present invention relates to antibodies and antigen-binding portions thereof that specifically bind to insulin-like growth factor I receptor (IGF-IR), which is preferably human IGF-IR. The invention also relates to human anti-IGF-IR antibodies, including chimeric, bispecific, derivatized, single chain antibodies or portions of fusion proteins. The invention also relates to isolated heavy and light chain immunoglobulin molecules derived from anti-IGF-IR antibodies and nucleic acid molecules encoding such molecules. The present invention also relates to methods of making anti-IGF-IR antibodies, pharmaceutical compositions comprising these antibodies and methods of using the antibodies and compositions thereof for diagnosis and treatment. The invention also provides gene therapy methods using nucleic acid molecules encoding the heavy and/or light immunoglobulin molecules that comprise the human anti-IGF-IR antibodies. The invention also relates to gene therapy methods and transgenic animals comprising nucleic acid molecules of the present invention.

Antibodies to insulin-like growth factor I receptor

The present invention relates to compositions and methods for treating the epithelial toxicity caused by administering to a human cancer patient an epidermal growth factor receptor (EGFR) inhibitor. The pharmaceutical composition preferably comprises an EGFR inhibitor and a keratinocyte growth factor (KGF) in a pharmaceutically-acceptable carrier. The method of treatment comprises co-administering to the patient a therapeutically effective amount of KGF with the EGFR inhibitor.

Combined treatment with keratinocyte growth factor and epidermal growth factor inhibitor

A method of monotherapy for a subject suffering from abnormal cell growth expressing the epidermal growth factor receptor (EGFR) which comprises orally administering to the subject a therapeutically effective amount of a crystalline polymorph of the hydrochloride salt of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine so as to treat the subject.

Treating abnormal cell growth with a stable polymorph of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine hydrochloride

The present invention relates to a stable crystalline form of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine hydrochloride designated the B polymorph, its production in essentially pure form, and its use. The invention also relates to the pharmaceutical compositions containing the stable polymorph B form of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine as hydrochloride, as well other forms of the compound, and to methods of treating hyperproliferative disorders, such as cancer, by administering the compound.

Stable polymorph on N-(3-ethynylphenyl)-6, 7-bis (2methoxyethoxy)-4-quinazolinamine hydrochloride, methods of production, and pharmaceutical uses thereof

Growing community of inventors

East Lyme, CT, United States of America

James Dale Moyer